186 related articles for article (PubMed ID: 23538388)
1. Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070.
O'Boyle G; Swidenbank I; Marshall H; Barker CE; Armstrong J; White SA; Fricker SP; Plummer R; Wright M; Lovat PE
Br J Cancer; 2013 Apr; 108(8):1634-40. PubMed ID: 23538388
[TBL] [Abstract][Full Text] [Related]
2. The molecular pharmacology of AMD11070: an orally bioavailable CXCR4 HIV entry inhibitor.
Mosi RM; Anastassova V; Cox J; Darkes MC; Idzan SR; Labrecque J; Lau G; Nelson KL; Patel K; Santucci Z; Wong RS; Skerlj RT; Bridger GJ; Huskens D; Schols D; Fricker SP
Biochem Pharmacol; 2012 Feb; 83(4):472-9. PubMed ID: 22146583
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Morimoto M; Matsuo Y; Koide S; Tsuboi K; Shamoto T; Sato T; Saito K; Takahashi H; Takeyama H
BMC Cancer; 2016 May; 16():305. PubMed ID: 27175473
[TBL] [Abstract][Full Text] [Related]
4. The
Pansy K; Feichtinger J; Ehall B; Uhl B; Sedej M; Roula D; Pursche B; Wolf A; Zoidl M; Steinbauer E; Gruber V; Greinix HT; Prochazka KT; Thallinger GG; Heinemann A; Beham-Schmid C; Neumeister P; Wrodnigg TM; Fechter K; Deutsch AJ
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554271
[TBL] [Abstract][Full Text] [Related]
5. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.
Parameswaran R; Yu M; Lim M; Groffen J; Heisterkamp N
Leukemia; 2011 Aug; 25(8):1314-23. PubMed ID: 21483439
[TBL] [Abstract][Full Text] [Related]
6. Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure.
Cox BD; Prosser AR; Katzman BM; Alcaraz AA; Liotta DC; Wilson LJ; Snyder JP
Chembiochem; 2014 Jul; 15(11):1614-20. PubMed ID: 24990206
[TBL] [Abstract][Full Text] [Related]
7. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.
Bi J; Li P; Li C; He J; Wang Y; Zhang H; Fan X; Jia R; Ge S
Tumour Biol; 2016 Mar; 37(3):4175-82. PubMed ID: 26490988
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic knockout of CXCR4 by a novel recombinant protein TAT/54R/KDEL inhibits tumors metastasis.
Ma WF; Du J; Fu LP; Fang R; Chen HY; Cai SH
Mol Cancer Res; 2009 Oct; 7(10):1613-21. PubMed ID: 19825996
[TBL] [Abstract][Full Text] [Related]
9. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
11. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210.
Johnson VA; Cramer YS; Rosenkranz SL; Becker S; Klingman KL; Kallungal B; Coakley E; Acosta EP; Calandra G; Saag MS;
AIDS Res Hum Retroviruses; 2019 Aug; 35(8):691-697. PubMed ID: 31099252
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the potential multiple binding modes of bicyclam, monocylam, and noncyclam small-molecule CXC chemokine receptor 4 inhibitors.
Wong RS; Bodart V; Metz M; Labrecque J; Bridger G; Fricker SP
Mol Pharmacol; 2008 Dec; 74(6):1485-95. PubMed ID: 18768385
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
Van Hout A; D'huys T; Oeyen M; Schols D; Van Loy T
PLoS One; 2017; 12(4):e0176057. PubMed ID: 28410420
[TBL] [Abstract][Full Text] [Related]
15. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
[TBL] [Abstract][Full Text] [Related]
17. Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization.
Jørgensen AS; Daugvilaite V; De Filippo K; Berg C; Mavri M; Benned-Jensen T; Juzenaite G; Hjortø G; Rankin S; Våbenø J; Rosenkilde MM
Commun Biol; 2021 May; 4(1):569. PubMed ID: 33980979
[TBL] [Abstract][Full Text] [Related]
18. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
19. Bone-derived Nestin-positive mesenchymal stem cells improve cardiac function via recruiting cardiac endothelial cells after myocardial infarction.
Lu D; Liao Y; Zhu SH; Chen QC; Xie DM; Liao JJ; Feng X; Jiang MH; He W
Stem Cell Res Ther; 2019 Apr; 10(1):127. PubMed ID: 31029167
[TBL] [Abstract][Full Text] [Related]
20. Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
Mendt M; Cardier JE
Melanoma Res; 2017 Aug; 27(4):300-308. PubMed ID: 28445180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
